BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 33117052)

  • 1. Onchocerciasis Elimination: Progress and Challenges.
    Lakwo T; Oguttu D; Ukety T; Post R; Bakajika D
    Res Rep Trop Med; 2020; 11():81-95. PubMed ID: 33117052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reaching the last mile: main challenges relating to and recommendations to accelerate onchocerciasis elimination in Africa.
    Gebrezgabiher G; Mekonnen Z; Yewhalaw D; Hailu A
    Infect Dis Poverty; 2019 Jul; 8(1):60. PubMed ID: 31269966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment and monitoring of onchocerciasis in Latin America.
    Rodríguez-Pérez MA; Unnasch TR; Real-Najarro O
    Adv Parasitol; 2011; 77():175-226. PubMed ID: 22137585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doxycycline plus ivermectin versus ivermectin alone for treatment of patients with onchocerciasis.
    Abegunde AT; Ahuja RM; Okafor NJ
    Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD011146. PubMed ID: 26771164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypo-endemic onchocerciasis hotspots: defining areas of high risk through micro-mapping and environmental delineation.
    Kelly-Hope LA; Unnasch TR; Stanton MC; Molyneux DH
    Infect Dis Poverty; 2015; 4():36. PubMed ID: 26279835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Research for new drugs for elimination of onchocerciasis in Africa.
    Kuesel AC
    Int J Parasitol Drugs Drug Resist; 2016 Dec; 6(3):272-286. PubMed ID: 27693536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurological manifestations in Onchocerca volvulus infection: A review.
    Hotterbeekx A; Namale Ssonko V; Oyet W; Lakwo T; Idro R
    Brain Res Bull; 2019 Feb; 145():39-44. PubMed ID: 30458251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Control of onchocerciasis.
    Boatin BA; Richards FO
    Adv Parasitol; 2006; 61():349-94. PubMed ID: 16735169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Community-directed vector control to supplement mass drug distribution for onchocerciasis elimination in the Madi mid-North focus of Northern Uganda.
    Jacob BG; Loum D; Lakwo TL; Katholi CR; Habomugisha P; Byamukama E; Tukahebwa E; Cupp EW; Unnasch TR
    PLoS Negl Trop Dis; 2018 Aug; 12(8):e0006702. PubMed ID: 30148838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization and evaluation of the Esperanza Window Trap to reduce biting rates of Simulium damnosum sensu lato in Northern Uganda.
    Loum D; Cozart D; Lakwo T; Habomugisha P; Jacob B; Cupp EW; Unnasch TR
    PLoS Negl Trop Dis; 2019 Jul; 13(7):e0007558. PubMed ID: 31310607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Final report of the Conference on the eradicability of Onchocerciasis.
    Dadzie Y; Neira M; Hopkins D
    Filaria J; 2003 Feb; 2(1):2. PubMed ID: 12605722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Onchocerciasis Elimination Program for the Americas (OEPA).
    Sauerbrey M
    Ann Trop Med Parasitol; 2008 Sep; 102 Suppl 1():25-9. PubMed ID: 18718151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Towards the elimination of onchocerciasis.
    Thylefors B; Alleman M
    Ann Trop Med Parasitol; 2006 Dec; 100(8):733-46. PubMed ID: 17227651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementation of test-and-treat with doxycycline and temephos ground larviciding as alternative strategies for accelerating onchocerciasis elimination in an area of loiasis co-endemicity: the COUNTDOWN consortium multi-disciplinary study protocol.
    Wanji S; Nji TM; Hamill L; Dean L; Ozano K; Njouendou AJ; Abong RA; Obie ED; Amuam A; Ekanya R; Ndongmo WPC; Ndzeshang BL; Fung EG; Nnamdi DB; Nkimbeng DA; Teghen S; Kah E; Piotrowski H; Forrer A; Khan JAM; Woode ME; Niessen L; Watson V; Njoumemi Z; Murdoch ME; Thomson R; Theobald S; Enyong P; Turner JD; Taylor MJ
    Parasit Vectors; 2019 Dec; 12(1):574. PubMed ID: 31801631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loa loa vectors Chrysops spp.: perspectives on research, distribution, bionomics, and implications for elimination of lymphatic filariasis and onchocerciasis.
    Kelly-Hope L; Paulo R; Thomas B; Brito M; Unnasch TR; Molyneux D
    Parasit Vectors; 2017 Apr; 10(1):172. PubMed ID: 28381279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress towards onchocerciasis elimination in the participating countries of the African Programme for Onchocerciasis Control: epidemiological evaluation results.
    Tekle AH; Zouré HG; Noma M; Boussinesq M; Coffeng LE; Stolk WA; Remme JH
    Infect Dis Poverty; 2016 Jun; 5(1):66. PubMed ID: 27349645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Filariasis in Africa--treatment challenges and prospects.
    Hoerauf A; Pfarr K; Mand S; Debrah AY; Specht S
    Clin Microbiol Infect; 2011 Jul; 17(7):977-85. PubMed ID: 21722251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elimination of human onchocerciasis: history of progress and current feasibility using ivermectin (Mectizan(®)) monotherapy.
    Cupp EW; Sauerbrey M; Richards F
    Acta Trop; 2011 Sep; 120 Suppl 1():S100-8. PubMed ID: 20801094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress towards the elimination of onchocerciasis as a public-health problem in Uganda: opportunities, challenges and the way forward.
    Ndyomugyenyi R; Lakwo T; Habomugisha P; Male B
    Ann Trop Med Parasitol; 2007 Jun; 101(4):323-33. PubMed ID: 17524247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of repeated annual community directed treatment with ivermectin on loiasis parasitological indicators in Cameroon: Implications for onchocerciasis and lymphatic filariasis elimination in areas co-endemic with Loa loa in Africa.
    Wanji S; Chounna Ndongmo WP; Fombad FF; Kengne-Ouafo JA; Njouendou AJ; Longang Tchounkeu YF; Koudou B; Bockarie M; Fobi G; Roungou JB; Enyong PA
    PLoS Negl Trop Dis; 2018 Sep; 12(9):e0006750. PubMed ID: 30226900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.